Program: Oral and Poster Abstracts
Type: Oral
Session: 623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological II
Hematology Disease Topics & Pathways:
Research, clinical trials, Biological therapies, Lymphomas, non-Hodgkin lymphoma, Bispecific Antibody Therapy, Clinical Research, B Cell lymphoma, Diseases, indolent lymphoma, Therapies, Lymphoid Malignancies
Monday, December 12, 2022: 4:30 PM
Tae Min Kim, MD, PhD1*, Michal Taszner, MD2*, Seok-Goo Cho, M.D., Ph.D.3*, Silvana Novelli, MD, PhD4, Steven Le Gouill, MD, PhD5, Michelle Limei Poon, MBBS, MRCP6*, Jose C. Villasboas, MD7, Rebecca Champion, MD8*, Emmanuel Bachy, MD, PhD9*, Stéphanie Guidez, MD10*, Aránzazu Alonso Alonso, MD11*, Deepa Jagadeesh, MD12, Michele Merli, MD13*, David Tucker, MD14*, Jingxian Cai15*, Carolina Leite De Oliveira, PharmD15*, Min Zhu, PhD15*, Aafia Chaudhry, MD, MBA, MS15*, Hesham Mohamed, MD15*, Srikanth R. Ambati, MBBS, MD15* and Stefano Luminari, MD16
1Seoul National University Hospital, Seoul, Korea, Republic of (South)
2Uniwersyteckie Centrum Kliniczne Klinika Hematologii I Transplantologii, Gdańsk, Poland
3The Catholic University of Korea, Seoul St. Mary’s Hospital Hematology, Seoul, Korea, Republic of (South)
4Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
5Hospital Group at Institute Curie, Paris, France
6Hematology Oncology National University Hospital, Singapore, Singapore
7Mayo Clinic Rochester, Rochester, NY
8Norton Cancer Institute, Louisville, KY
9Hospices Civils de Lyon and Université Claude Bernard Lyon 1, Lyon, France
10Centre Hospitalier Universitaire (CHU) de Poitiers, Poitiers, France
11Hospital Universitario Quiron Salud Madrid, Madrid, Spain
12Cleveland Clinic Main Campus, Cleveland, OH
13Hematology, Ospedale di Circolo e Fondazione Macchi, Varese, Italy
14Royal Cornwall Hospital, Cornwall, United Kingdom
15Regeneron Pharmaceuticals, Inc., Tarrytown, NY
16Division of Hematology, Azienda Unità Sanitaria Locale-IRCCS, Reggio Emilia, Italy
Background
Odronextamab is a hinge-stabilized, human IgG4-based CD20×CD3 bispecific antibody that binds CD20 on B cells and CD3 on T cells, triggering T-cell-mediated cytotoxicity of malignant B cells. In ELM-1 (Ph1, NCT02290951), pts with FL Grade 1–3a receiving ≥2 prior lines of therapy and treated with odronextamab doses of ≥5 mg, had an ORR of 91% and CR rate of 72%. Responses were durable with a 4-y PFS rate of 54% (Bannerji R, et al. Lancet Haematol. 2022). The RP2D dose in R/R FL pts was determined as 80 mg weekly. Here, we present for the first time, results from a prespecified analysis of the FL Grade 1–3a cohort from the pivotal ELM-2 study (Ph2, NCT03888105), which incorporated an optimized step-up regimen designed to maintain efficacy while minimizing acute toxicity including cytokine release syndrome (CRS).
Methods
ELM-2 is a global, multicenter study enrolling pts at 91 sites in 13 countries. Adult pts with FL Grade 1–3a who had relapsed or were refractory to ≥2 prior lines of therapy including an anti-CD20 antibody and alkylator were enrolled. IV odronextamab was administered in 21-day cycles with steroid prophylaxis and weekly step-up dosing during Cycle (C) 1 to mitigate risk of acute toxicity. The initial step-up regimen consisted of 1 mg split over C1 Day (D) 1 and C1D2, and 20 mg split over C1D8 and C1D9, followed by the 80 mg full dose on C1D15 (1/20 regimen). The 1/20 regimen was revised during the study to further mitigate CRS risk by adding an intermediary step-up dose. The modified regimen consisted of 0.7 mg split over C1D1 (0.2 mg) and C1D2 (0.5 mg), 4 mg split over C1D8 and C1D9, and 20 mg split over C1D15 and C1D16, followed by the 80 mg full dose on C2D1 (0.7/4/20 regimen). 80 mg weekly continued until the end of C4. After C4, maintenance treatment with 160 mg odronextamab occurred every 2 wks until disease progression or unacceptable toxicity. The primary endpoint was ORR assessed by independent central review (ICR) according to Lugano 2014 criteria. CRS was assessed using 2019 ASTCT criteria.
Results
As of April 20, 2022, 96 pts were evaluable for safety; 85 for efficacy. Median age 59 y (range 22–84), 52% male, 58% FLIPI 3–5, 15.6% had bulky disease, and median prior lines of therapy were 3 (range 2–13). 74% were refractory to their last therapy, 79% refractory to prior anti-CD20 therapy, and 48% had progression of disease within 2 y (POD24). Median duration of study follow-up was 17.3 mos. ORR and CR rate by ICR were 81% (69/85) and 75% (64/85), respectively. ORR and CR rate were consistent across high-risk subgroups, including pts aged ≥65 y, POD24, FLIPI 3–5, and pts refractory to their last line of therapy; ORR and CR rate were also consistent for the subgroup of pts treated with the 0.7/4/20 step-up regimen. Responses were durable with both a median duration of response and a median duration of CR of 18.2 mos. Median PFS was 20.2 mos (95% CI 14.8–not estimable [NE]) and median OS was not reached (95% CI 23.0 mos–NE).
TEAEs occurred in 95 (99%) pts, considered treatment related in 86 (90%). In the overall safety evaluable population, the most common TEAEs (>30% all grades) were CRS (51%), pyrexia (32%), anemia (31%), and infusion-related reaction (31%). Following implementation of the 0.7/4/20 step-up regimen in C1, no Grade ≥2 CRS was observed; only Grade 1 CRS was reported in 39% of pts. All CRS events resolved and only 1 pt received tocilizumab for CRS management. No ICANS was reported in the 0.7/4/20 regimen compared with 3% in the 1/20 regimen. COVID-19 was reported (n=13,14%), including Grade ≥3 (n=5, 5%). Treatment-related Grade 5 AEs were reported for 2 pts; treatment-related AEs led to discontinuation in 6 pts.
Conclusions
Consistent with the ELM-1 Ph1 study, the ELM-2 pivotal Ph2 study of odronextamab demonstrated compelling efficacy in pts with FL Grade 1–3a receiving ≥2 prior lines of therapy, with 75% of pts achieving CR by ICR and an acceptable safety profile. Durability of responses and favorable survival outcomes are clinically important in the context of heavily pretreated, highly R/R FL, where prognosis is typically poor. The 0.7/4/20 step-up regimen compares favorably to other CD20×CD3 bispecifics, with no Grade 2 or higher CRS reported. Odronextamab may represent an important treatment option for R/R FL, providing a more accessible option with favorable benefit/risk compared with existing therapies including CAR T cell therapy. Updated safety and efficacy data will be presented.
Disclosures: Kim: Celgene: Other: Clinical trial research funding to my institution; Boryung: Consultancy, Other: Clinical trial research funding to my institution; Boehringer-Ingelheim: Other: Clinical trial research funding to my institution; BMS: Other: Clinical trial research funding to my institution; Bayer: Consultancy, Other: Clinical trial research funding to my institution; AstraZeneca/MedImmune: Consultancy, Other: Clinical trial research funding to my institution; Takeda: Consultancy, Honoraria, Other: Clinical trial research funding to my institution; Roche/Genentech: Consultancy, Honoraria, Other: Clinical trial research funding to my institution; Novartis: Consultancy, Honoraria, Other: Clinical trial research funding to my institution; Janssen: Consultancy, Honoraria, Other: Clinical trial research funding to my institution; Hanmi: Consultancy, Honoraria, Other: Clinical trial research funding to my institution; AstraZeneca: Honoraria; AstraZeneca-KHIDI: Research Funding; Genmab: Other: Clinical trial research funding to my institution; Merck Serono: Other: Clinical trial research funding to my institution; Merck Sharp & Dohme: Other: Clinical trial research funding to my institution; Regeneron: Consultancy, Other: Clinical trial research funding to my institution; Sanofi: Other: Clinical trial research funding to my institution. Taszner: Roche: Consultancy, Honoraria, Research Funding; Novartis: Consultancy, Honoraria; BeiGene: Research Funding. Novelli: Mundipharma: Consultancy; Novartis: Research Funding. Le Gouill: Novartis, Kite/Gilead, Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel support. Villasboas: Aptose: Research Funding; CRISPR: Research Funding; Enterome: Research Funding; Epizyme: Research Funding; Kite Pharma: Research Funding; Regeneron: Research Funding. Champion: AbbVie: Speakers Bureau; Bristol Myers Squibb: Speakers Bureau. Bachy: Roche, Gilead, ADC Therapeutics, Takeda, Novartis, Incyte: Membership on an entity's Board of Directors or advisory committees; Kite, Gilead, Novartis, Roche, Incyte, Miltenyi Biotech, Takeda, Sanofi: Honoraria; Hospices Civils de Lyon: Current Employment; Amgen, BMS: Research Funding. Guidez: Gilead Kite: Honoraria; Takeda: Honoraria; Incyte: Honoraria; AstraZeneca: Honoraria. Alonso Alonso: AbbVie: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Incyte: Consultancy, Honoraria; GlaxoSmithKline: Consultancy, Honoraria. Jagadeesh: ATARA Biotherapeutics: Research Funding; AstraZeneca: Research Funding; Affimed: Membership on an entity's Board of Directors or advisory committees; LOXO Pharmaceuticals: Research Funding; Debio pharma: Research Funding; Regeneron Pharmaceuticals, Inc.: Research Funding; MEI Pharma: Research Funding; Seagen: Research Funding; Daiichi Sankyo: Consultancy, Membership on an entity's Board of Directors or advisory committees; Trillium Pharmaceuticals: Research Funding. Tucker: Immunovant Corps: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees. Cai: Regeneron Pharmaceuticals, Inc.: Current Employment, Current equity holder in private company, Current equity holder in publicly-traded company, Current holder of stock options in a privately-held company. Leite De Oliveira: Regeneron Pharmaceuticals, Inc.: Current Employment, Current equity holder in private company, Current holder of stock options in a privately-held company. Zhu: Regeneron Pharmaceuticals, Inc.: Current Employment, Current equity holder in private company, Current equity holder in publicly-traded company, Current holder of stock options in a privately-held company. Chaudhry: Regeneron Pharmaceuticals, Inc.: Current Employment, Current equity holder in private company, Current equity holder in publicly-traded company, Current holder of stock options in a privately-held company. Mohamed: Regeneron Pharmaceuticals, Inc.: Current Employment, Current equity holder in private company, Current equity holder in publicly-traded company, Current holder of stock options in a privately-held company. Ambati: Regeneron Pharmaceuticals, Inc.: Current Employment, Current equity holder in private company, Current equity holder in publicly-traded company, Current holder of stock options in a privately-held company. Luminari: Roche: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; BMS: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Kite: Membership on an entity's Board of Directors or advisory committees.
OffLabel Disclosure: Odronextamab for the treatment of patients with follicular lymphoma.
See more of: 623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological II
See more of: Oral and Poster Abstracts
Previous Abstract|Next Abstract >>
*signifies non-member of ASH
FAQs
What is the mechanism of action of Odronextamab? ›
The primary mechanism of action of odronextamab is directed T cell-mediated killing of CD20+ target cells. Odronextamab binds Fcγ receptors with no or low affinity, does not induce antibody-dependent cell-mediated cytotoxicity (ADCC), and shows weak complement dependent cytotoxicity (CDC) activity.
What is odronextamab? ›Odronextamab is an investigational bispecific antibody designed to bridge CD20 on cancer cells with CD3-expressing T cells to facilitate local T-cell activation and cancer-cell killing.
What does CD3 and CD20 positive mean? ›CD20 and CD3 are commonly used as specific markers of B and T lineage lymphomas, respectively. Lymphoid aggregates homogenously stained with anti-CD3 in T lineage lymphoma and anti-CD20 in B lineage lymphoma are generally considered confirmatory of malignant lymphoma cell infiltration into the BM [12].
Is Odronextamab FDA approved? ›In the U.S. , odronextamab has been granted Fast Track Designation for FL by the FDA. In the European Union , Orphan Drug Designation was granted for FL by the European Medicines Agency .
What is the name of REGN1979? ›BACKGROUND: Odronextamab (REGN1979) is a first-in-class, hinge-stabilized, fully human IgG4-based CD3 x CD20 bispecific antibody (bsAb) that has demonstrated encouraging safety, tolerability and preliminary efficacy in a first-in-human study of patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma ( ...
What cancers are CD20 positive? ›A protein found on B cells (a type of white blood cell). It may be found in higher than normal amounts in patients with certain types of B-cell lymphomas and leukemias.
What disease is CD20 positive? ›CD20 positive T cell lymphoma is a rare condition that is characterized by the coexpression of CD20 and T cell markers, such as, CD3, CD5, or UCHL-11. Positivity for CD20 in any type of T cell lymphoma represents an aberrant immunophenotype, despite the presence of various indicators of T cell lymphoma.
What are the markers for non-Hodgkin's lymphoma? ›COMMON MARKERS OF LYMPHOMA
CD19, Pax-5 and TdT are early B-cell differentiation markers expressed in precursor B-cells. Later, CD20, Pax-5 and CD79a control further B-cell differentiation and, are also considered as markers of B-cell lineage.
- Drugs@FDA lists most prescription and over-the-counter (OTC) drug products approved since 1939. ...
- The FDA "Orange Book" contains drugs approved by FDA under New Drug Applications (NDAs) and Abbreviated New Drug Applications (ANDAs).
Nanotechnology Research at NCTR
The FDA has already reviewed and approved some nanotechnology-based products, and expects a significant increase in the use of nanoscale materials in drugs, devices, biologics, cosmetics, and food.
How do you check if a drug is FDA approved? ›
Look up the drug in Drugs @ FDA.
Most FDA-approved human drugs and therapeutic biologic products are listed in Drugs @ FDA, a searchable database. The database allows you to search by drug name, active ingredient, or application (NDA, ANDA, or BLA) number.
A cluster with >20 CD3-positive cells is a candidate indicator for BM involvement in PTCL. Keywords: Peripheral T-cell lymphoma, Bone marrow involvement, CD3 positivity. Peripheral T-cell lymphomas, not otherwise specified (PTCLs) represent approximately 10% of all non-Hodgkin lymphomas [1].
What does CD3 test for? ›The CD3 absolute count test is a serological test used to determine CD3, CD4, and CD8 levels in the blood. This test is used to diagnose T cell lymphoma, a type of cancer of the lymphocytes (white blood cells).
What is the significance of CD3? ›The CD3–T cell receptor (TCR) complex plays a central role in the T-cell-mediated immunoresponse as it is involved in the recognition of antigens and subsequent signal transduction and activation of immunocompetent T lymphocytes.
What do CD20 positive B cells do? ›Not only do they produce autoantibodies, but they regulate other cell types, secrete cytokines, and present antigens. They are thus potential targets for therapeutic intervention. CD20 is a B-cell specific cell surface molecule of uncertain function.